Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02991768 · ClinicalTrials.gov registry record · Phase 2
Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02991768: Clinical Trial Phase 2 study, sponsored by University of Kansas Medical Center.
NCT02991768 is a Phase 2 study that was terminated before completion, run by University of Kansas Medical Center. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02991768, a Phase 2 study, was terminated before completion, sponsored by University of Kansas Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if using a Entocort (budesonide) to treat diarrhea will be effective and safe for kidney transplant patients, allowing them to continue with MPA medication.
Primary Outcome
Measured using symptom diary. Complete remission (CR) is defined as a mean of \<3 stools/day and a mean of \<1 watery stool per day without use of anti-diarrheal drugs.
Interventions
- DRUG Placebos
- DRUG Entocort
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-01-27 |
| Est. Completion | 2019-04-26 |
| Phase | Phase 2 |
Why NCT02991768 stopped before completion
NCT02991768 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT02991768 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02991768 about?
NCT02991768 is a clinical study titled "Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients". The purpose of this study is to learn if using a Entocort (budesonide) to treat diarrhea will be effective and safe for kidney transplant patients, allowing them to continue with MPA medication.
What is the current status of trial NCT02991768?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2017-01-27. Estimated completion is 2019-04-26.
What interventions are being tested in trial NCT02991768?
The interventions under investigation include: Placebos (DRUG), Entocort (DRUG).
Who is sponsoring clinical trial NCT02991768?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02991768's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI